Overview

A Study in Subjects With Late Prodromal and Early Manifest Huntington's Disease (HD) to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Pepinemab (VX15/2503)

Status:
Completed

Trial end date:
2020-08-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety, tolerability, PK, and efficacy of VX15/2503 in subjects with late prodromal and early manifest Huntington's disease.

Phase:

Phase 2

Details

Lead Sponsor:

Vaccinex Inc.

Collaborator:

Huntington Study Group